Who we are

We are a German clinical-stage biotech company based near Munich and world-wide connected. Our focus lies on fighting cancer as one of the most devastating civilization disease of the 21st century and we strive to improve patients' lives by bringing innovation from lab to patients.

What strategy we follow

We identify and invest in academic cancer research projects to develop them from early stage to clinical proof of concept, before final development and marketing by a pharma partner is facilitated. Our multi-stage project selection process, together with our lean operating structure that combines in-house expertise with outsourced execution, ensures a capital-efficient pipeline development, creating maximum value for patients and our investors.

Teamwork is the key

We are a team and live real teamwork. In this way, we benefit best from the extensive experience of our individuals:

Dr. Bernard Huber

Chief Executive Officer

Dr. Dr. Michael Dahm

Chief Medical Officer

Dr. Ottheinz Krebs

Chief Operating Officer

Dr. Fabian Huber, LL.M.

General Counsel

We trust in our Advisors and partners

Our advisors and partners are world-renowned and among the best in their discipline. Through our close connection to them, we ensure hand in hand development of our pipeline in a trustworthy and professional setting. Among others, our partners include: